Roivant Sciences/ROIV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Roivant Sciences

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor in development across several IgG-mediated autoimmune indications; and brepocitinib, a TYK2/JAK1 inhibitor in late stage development for dermatomyositis, non-infectious uveitis, and other autoimmune conditions, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Ticker

ROIV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Matthew Gline

Employees

845

Headquarters

London, United Kingdom

Roivant Sciences Metrics

BasicAdvanced
$7.7B
Market cap
2.04
P/E ratio
$5.07
EPS
1.25
Beta
-
Dividend rate
$7.7B
1.24852
$13.24
$8.25
6.9M
25.236
25.104
7.214
7.415
0.48
88.04%
122.05%
103.92%
2.045
61.326
1.4
1.313
103.65%
421.45%
73.74%

What the Analysts think about Roivant Sciences

Analyst Ratings

Majority rating from 11 analysts.
Buy

Roivant Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-522.83% profit margin
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$29M
-22.10%
Net income
-$151M
-102.97%
Profit margin
-522.83%
-103.81%

Roivant Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 37.36%
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.38
-$0.40
$6.03
-$0.19
-
Expected
-$0.30
-$0.31
-$0.32
-$0.30
-$0.29
Surprise
27.69%
29.63%
-1,984.38%
-37.36%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Roivant Sciences stock?

Roivant Sciences (ROIV) has a market cap of $7.7B as of June 17, 2024.

What is the P/E ratio for Roivant Sciences stock?

The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 2.04 as of June 17, 2024.

Does Roivant Sciences stock pay dividends?

No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Roivant Sciences dividend payment date?

Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.

What is the beta indicator for Roivant Sciences?

Roivant Sciences (ROIV) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Roivant Sciences stock price target?

The target price for Roivant Sciences (ROIV) stock is $16.5, which is NaN% below the current price of $. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Roivant Sciences stock

Buy or sell Roivant Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing